Patents Examined by Timothy R Rozof
  • Patent number: 10865217
    Abstract: The present invention relates to process for the preparation of 5-(4-cyano phenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole represented by the following structural formula-1 and polymorphs thereof. The present invention also relates to salts of 5-(4-cyano phenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and process for their preparation and their use in the preparation of pure compound of the formula-1.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: December 15, 2020
    Assignee: MSN LABORATORIES PRIVATE LIMITED, R & D CENTER
    Inventors: Thirumalai Rajan Srinivasan, Eswaraiah Sajja, Venkat Reddy Ghojala, Markandeya Bekkam
  • Patent number: 10858337
    Abstract: A method for preparing 1,1?-ethylene-2,2?-bipyridinium dichloride includes mixing an aqueous diquat dibromide solution with hydrochloric acid, adding dropwise to a mixture of an organic solvent, a bromine absorbent, and an oxidant, and reacting to produce 1,1?-ethylene-2,2?-bipyridinium dichloride.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: December 8, 2020
    Assignee: NANJING REDSUN BIOCHEMISTRY CO., LTD.
    Inventors: Ruikuan Yue, Yi Xue, Honglong Chen, Wenkui Wang, Chaoran Luo, Xinchun Chen, Dianhai Zhou, Jianhua Jiang, Fujun Wang
  • Patent number: 10851071
    Abstract: Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 1, 2020
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Xiaobing Yan, Wei Huang, Dan Li, Charles Z. Ding, Fei Liu, Xiquan Zhang
  • Patent number: 10844031
    Abstract: The present application relates to a process for preparation of a compound of Formula (I) and Formula (IV): wherein is as described herein; and wherein and R are as described herein.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 24, 2020
    Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Aaron David Sadow, Zachary Benjamin Weinstein, George A. Kraus
  • Patent number: 10836750
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: November 17, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Patent number: 10836744
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: November 17, 2020
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • Patent number: 10829465
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: November 10, 2020
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
  • Patent number: 10829463
    Abstract: The invention relates to a process for separating furanic compounds from a feedstock additionally containing dimethoxysulfoxide (DMSO). These furanic compounds are in particular 5-hydroxymethylfurfural (5-HMF), 2,5-diformylfuran (DFF), 2,5-furanedicarboxylic acid (FDCA) or dimethyl 2,5-furandicarboxylate (DMFDCA). The process successively comprises a) bringing the feedstock into contact with water originating from step c), then b) a liquid-liquid extraction with an organic solvent followed by a back extraction c) by the water added in order to obtain an organic extract rich in furanic compounds. The extract may then be subjected to a crystallization step d) and then a filtration in order to obtain the solid furanic compound. The water-rich or solvent-rich effluents are advantageously recycled respectively to the back extraction and the extraction.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 10, 2020
    Assignee: IFP Energies Nouvelles
    Inventors: Marc Jacquin, Sophie Drozdz
  • Patent number: 10822332
    Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 3, 2020
    Assignee: DAMIAN PHARMA AG
    Inventors: Christoph Schumacher, Walter Fuhrer, Ronald Edward Steele
  • Patent number: 10822322
    Abstract: The present invention provides a new compound of formula (I): extracted from a seaweed, and its use for inhibiting the growth of cancer cells, as well as methods for its extraction and isolation.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: November 3, 2020
    Assignee: OCEANS LTD.
    Inventors: Judith Bobbitt, Ahmed Zein
  • Patent number: 10807956
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: October 20, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 10807931
    Abstract: Method for decarboxylating a carboxylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C1-C5 alkyl; R2 is selected from the group consisting of: OH or O, and R3 is selected from the group consisting of: a substituted or unsubstituted cyclohexene, a substituted or unsubstituted C2-C8 alkene, or a substituted or unsubstituted C2-C8 dialkene; or R2 is O, and R2 and R3 together form a ring structure in which R2 is an internal ring atom; wherein the method includes heating a reaction mixture comprising the carboxylated phytocannabinoid compound and a polar aprotic solvent in the presence of a LiCl for a time sufficient to decarboxylate at least a portion of the carboxylated phytocannabinoid compounds and form the phytocannabinoid compound.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 20, 2020
    Assignee: THE UNIVERSITY OF SYDNEY
    Inventors: Tristan Reekie, Michael Scott, Michael Kassiou
  • Patent number: 10806716
    Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: October 20, 2020
    Assignees: Auransa Inc., SCT II LLC
    Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
  • Patent number: 10799492
    Abstract: The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 13, 2020
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventor: Clas Sonesson
  • Patent number: 10799495
    Abstract: A benzodiazepine alkaloid compound and a pharmaceutically acceptable salt thereof, the structure of the compound being shown in general formula (I). in the formula (I), R1, R2 and R3 independently are hydrogen, C1-4 alkyl or C1-4 alkanoyl; one from among R4 and R5 is a benzene ring or a substituted benzene ring, while the other is hydrogen, a benzene ring or a substituted benzene ring, wherein a substituent group on the substituted benzene ring is hydroxyl, cyano, amino, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamine, C1-4 alkanoyl or C1-4 alkoxyacyl. A method for synthesizing the compound and a use in the preparation of anti-tumor drugs. The compound shown in formula (I) may be used for preparing anti-tumor, especially anti-lung cancer, drugs as well as anti-fungal drugs.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 13, 2020
    Assignee: RENJI HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Houwen Lin, Fan Yang
  • Patent number: 10793553
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Patent number: 10793514
    Abstract: The present disclosure provides compounds of formula: wherein R1, R2, and n are defined as set forth in the specification, and related aminobutanoic acids. The present disclosure also provides compositions comprising these compounds and methods for modulating ASCT2 function in a patient in need thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 6, 2020
    Assignee: Vanderbilt University
    Inventors: H. Charles Manning, Michael Schulte
  • Patent number: 10793549
    Abstract: The present invention relates to a sulfuryl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: October 6, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yunzhou Jin, Xiang Chen, Pengfei Cheng, Ping Bu, Leitao Zhang, Chong Wen, Yingtao Liu, Fusheng Zhou, Ming Weng, Jiong Lan
  • Patent number: 10792365
    Abstract: A peptide derivative represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents an oxygen atom or NR, Y represents NH2, N(Me)H, SH, OH, or phenyl in which any one of hydrogen atoms is replaced by NH2 or OH, and R represents a hydrogen atom or C1-C3 alkyl, provided that the derivative where X is NH, and Y is NH2, and the derivative where X is NH, and Y is N(Me)H are excluded.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 6, 2020
    Assignee: Toray Industries, Inc.
    Inventors: Yukihiro Nishio, Shinya Yokosaka
  • Patent number: 10793583
    Abstract: Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Robert Boyd